Use of the highest tested dose of asciminib, 200 mg BID, was justified by overall major molecular response (MMR; BCR::ABL1IS ≤0.1%) rates predicted by pharmacokinetic/pharmacodynamic analysis in patients with T315I-mutated CML-CP and may improve the probability of response by maximizing the predicted proportion of patients with asciminib exposure above the preclinical 90% maximal effective concentration [28]. This evidence concerns the gene CP and chronic myelogenous leukemia, BCR-ABL1 positive.